US Stock MarketDetailed Quotes
ENSC Ensysce Biosciences
- 0.4906
- -0.0594-10.80%
Trading Dec 4 10:11 ET
9.60MMarket Cap-252P/E (TTM)
0.5197High0.4900Low1.48MVolume0.5050Open0.5500Pre Close744.05KTurnover10.21%Turnover RatioLossP/E (Static)19.57MShares2.060052wk High1.39P/B7.10MFloat Cap0.141252wk Low--Dividend TTM14.48MShs Float5757.6000Historical High--Div YieldTTM5.40%Amplitude0.1412Historical Low0.5030Avg Price1Lot Size
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Ensysce Biosciences Stock Forum
Ensysce Biosciences (NASDAQ:ENSC) has announced a strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR drug products. The partnership includes a $10 million commitment and involves the manufacturer taking an equity position in Ensysce.
The collaboration will provide Ensysce with clinical trial material, drug products for regulatory submissions, and initial commercial batches. T...
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Tuesday, 3rd December at 4:15 pm
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on Friday, December 6, 2024, effective at 12:01 a.m. Eastern Time, it will imp...
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Ensysce Biosciences (NASDAQ:ENSC)has initiated dosing in the PF614-MPAR-102 study, marking a significant milestone for its breakthrough therapy-designated opioid drug.
The trial aims to evaluate the pharmacokinetics of oxycodone and PF614 when co-administered with nafamostat.
The study received a $14 million multi-year award from NIDA and expect...
No comment yet